Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic–hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study
Authors' conclusion
Administration of the SSTR2 antagonist ZT-01 increased glucagon responsiveness during insulin-induced hypoglycaemia in individuals with type 1 diabetes.
Study context
- Population
- Adults aged 18–65 years, BMI 18.5–27 kg/m², with T1D (HbA1c 42.1–74.9 mmol/mol, C-peptide <200 pmol/l), undergoing hyperinsulinaemic euglycaemic-hypoglycaemic clamps22 in pharmacodynamics analysis
- Participants
- 24 adults
- Comparison
- ZT-01 vs placebo
- Primary endpoint
- Glucagon response
Methodological detailsphase 1b, single-site, blinded to participants and researchers
- Phase 1b
- Single-site
- Blinded to participants and researchers
Primary result
As reported in the abstract
- Post-dose transient increase in plasma glucagon, 3 mg ZT-01
- 25.7 ± 2.4 ng/l
- Post-dose transient increase in plasma glucagon, 20 mg ZT-01
- 28.4 ± 2.4 ng/l
- Rise in glucagon over baseline during level 1 hypoglycaemia, 3 mg ZT-01
- 15.6 ± 2.3 pg/l
- Rise in glucagon over baseline during level 1 hypoglycaemia, 20 mg ZT-01
- 14.9 ± 2.4 pg/l
- Rise in glucagon over baseline during level 2 hypoglycaemia, 3.0 mg ZT-01
- 22.8 ± 2.7 pg/l
- Rise in glucagon over baseline during level 2 hypoglycaemia, 20 mg ZT-01
- 29.6 ± 2.8 pg/l
- Rise in glucagon during level 2 hypoglycaemia, placebo
- 8.9 ± 2.5 ng/l
Safety
- No drug treatment-related adverse events
Original publication
Effect of somatostatin receptor 2 antagonism on glucagon counterregulation during a hyperinsulinaemic euglycaemic–hypoglycaemic glucose clamp in adult men and women with long-standing type 1 diabetes: a randomised crossover phase 1 study. Diabetologia. Published 21 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →